Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia
Stopped Terminated per PI's request at the time of CR. Study was closed due to low/slow accrual due to other competing studies.
Conditions
- Accelerated Phase Chronic Myelogenous Leukemia (CML)
- Blast Phase Chronic Myelogenous Leukemia (CML)
- Chronic Phase Phase Chronic Myelogenous Leukemia (CML)
- Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)
Interventions
- DRUG: Axitinib
- DRUG: Bosutinib
- OTHER: Laboratory Biomarker Analysis
Sponsor
M.D. Anderson Cancer Center
Collaborators